Canada - GBIP application success
We excited to announce that Alcyomics has been selected to participate in the prestigious Global Business Innovation Programme (GBIP) in Canada. This remarkable accomplishment reaffirms Alcyomics’ commitment to pushing the boundaries of innovation in the field of biomanufacturing.
The GBIP, organized by Innovate UK and the Canadian Trade Commissioner Service, is an international program that connects innovative UK companies with global market opportunities. This year, the program’s focus on biomanufacturing of biologics and advanced therapies aligns perfectly with Alcyomics’ core expertise in safety assessment aspects of process development.
The GBIP offers participants a unique platform to engage with Canadian partners and industry experts, fostering collaborations and knowledge exchange. This opportunity will allow Alcyomics to gain insights into Canada’s biomanufacturing ecosystem, establish valuable connections, and explore avenues for future expansion.
Prof. Anne Dickinson, CEO of Alcyomics, expressed her enthusiasm for the program, stating, “Being chosen to participate in the Global Business Innovation Programme is a testament to the ground-breaking work Alcyomics is doing in biotechnology safety field. We are excited to collaborate with Canadian partners and explore new opportunities that will further enhance our contributions to the biologics and advanced therapies sector.”
The selection of Alcyomics for the GBIP underscores the company’s dedication to advancing healthcare solutions and our commitment to fostering international collaborations. As we embark on this exciting journey, Alcyomics is poised to make significant strides in the biomanufacturing sector while contributing to the global advancement of biologics and advanced therapies.
